Emily S Chambers
Overview
Explore the profile of Emily S Chambers including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
324
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bondeson D, Paolella B, Asfaw A, Rothberg M, Skipper T, Langan C, et al.
Nat Cancer
. 2022 Apr;
3(6):681-695.
PMID: 35437317
Despite advances in precision medicine, the clinical prospects for patients with ovarian and uterine cancers have not substantially improved. Here, we analyzed genome-scale CRISPR-Cas9 loss-of-function screens across 851 human cancer...
2.
Haikala H, Lopez T, Kohler J, Eser P, Xu M, Zeng Q, et al.
Cancer Res
. 2021 Sep;
82(1):130-141.
PMID: 34548332
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) are the standard-of-care treatment for -mutant non-small cell lung cancers (NSCLC). However, most patients develop acquired drug resistance to EGFR TKIs....
3.
Eser P, Paranal R, Son J, Ivanova E, Kuang Y, Haikala H, et al.
Sci Transl Med
. 2021 Sep;
13(609):eabb3738.
PMID: 34516823
The clinical efficacy of epidermal growth factor receptor (EGFR)–targeted therapy in -mutant non–small cell lung cancer is limited by the development of drug resistance. One mechanism of EGFR inhibitor resistance...
4.
Kohler J, Zhao Y, Li J, Gokhale P, Tiv H, Knott A, et al.
Mol Cancer Ther
. 2021 Feb;
20(4):641-654.
PMID: 33536188
gene mutations are the most frequent oncogenic event in lung cancer. They activate multiple RAS-centric signaling networks among them the MAPK, PI3K, and RB pathways. Within the MAPK pathway, ERK1/2...
5.
Cooper A, Kobayashi Y, Kim D, Clifford S, Kravets S, Dahlberg S, et al.
Clin Cancer Res
. 2020 Apr;
26(15):4072-4079.
PMID: 32312893
Purpose: We pursued genomic analysis of an exceptional responder with non-small cell lung cancer (NSCLC) through a multi-platform effort to discover novel oncogenic targets. Experimental Design: In this open-label, single-arm...
6.
Guerra S, Maertens O, Kuzmickas R, De Raedt T, Adeyemi R, Guild C, et al.
Cancer Cell
. 2020 Apr;
37(5):705-719.e6.
PMID: 32243838
While KRAS mutations are common in non-small cell lung cancer (NSCLC), effective treatments are lacking. Here, we report that half of KRAS-mutant NSCLCs aberrantly express the homeobox protein HOXC10, largely...
7.
Ogino A, Choi J, Lin M, Wilkens M, Calles A, Xu M, et al.
Mol Oncol
. 2020 Mar;
15(1):27-42.
PMID: 32191822
Small-cell lung cancer (SCLC) occurs infrequently in never/former light smokers. We sought to study this rare clinical subset through next-generation sequencing (NGS) and by characterizing a representative patient-derived model. We...
8.
Ivanova E, Kuraguchi M, Xu M, Portell A, Taus L, Diala I, et al.
Clin Cancer Res
. 2020 Feb;
26(10):2393-2403.
PMID: 32034078
Purpose: Evaluating drug responses using primary patient-derived cells represents a potentially rapid and efficient approach to screening for new treatment approaches. Here, we sought to identify neratinib combinations in mutant...
9.
Bahcall M, Awad M, Sholl L, Wilson F, Xu M, Wang S, et al.
Clin Cancer Res
. 2018 Aug;
24(23):5963-5976.
PMID: 30072474
Purpose: MET inhibitors can be effective therapies in patients with exon 14 (ex14) mutant non-small cell lung cancer (NSCLC). However, long-term efficacy is limited by the development of drug resistance....
10.
Nishino M, Ramaiya N, Chambers E, Adeni A, Hatabu H, Janne P, et al.
J Immunother Cancer
. 2016 Dec;
4:84.
PMID: 28018599
Background: Tumor response characteristics using immune-related RECIST1.1 (irRECIST1.1) in advanced non-small-cell lung cancer (NSCLC) patients treated with nivolumab monotherapy in the clinical setting have not been previously described with a...